^
    Back
    Association details:
    Biomarker:EGFRvIII expression
    Cancer:Glioblastoma
    Drug:AMG 595 (Microtubule inhibitor, EGFRvIII-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

    Excerpt:
    Incubation of AMG 595 with U251 cells expressing EGFRvIII led to potent growth inhibition. AMG 595 treatment induced significant tumor mitotic arrest, as measured by phospho-histone H3, in GBM subcutaneous xenografts expressing EGFRvIII….These results demonstrate that AMG 595 is a promising candidate to evaluate in EGFRvIII-expressing GBM patients.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-14-1078